Zipalertinib

Taiho Oncology and Cullinan Therapeutics presented data at ESMO 2025 on zipalertinib, an EGFR tyrosine kinase inhibitor, for NSCLC patients with EGFR exon 20 insertion or uncommon mutations and CNS involvement. The REZILIENT2 study showed a 31.3% intracranial ORR and 68.8% iDCR in patients with measurable CNS disease treated with zipalertinib. Median intracranial DOR was 8.1 months. The drug demonstrated manageable side effects. These results suggest potential for zipalertinib in treating this patient population with limited options, warranting further investigation.